Keywords: nearly, patients, tibotec, hcv, drug, see, undetectable

Nearly 90% of patients on Tibotec's HCV drug see undetectable viral load

Article | 10 November 2008

Print This

Irish drugmaker Tibotec Pharmaceuticals presented strong findings on its protease inhibitor TMC435 from a Phase IIa trial in hepatitis C ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in